L-GILZ binds and inhibits nuclear factor κB nuclear translocation in undifferentiated thyroid cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• Proto-oncogene mutations and aberrant mitogen-activated protein kinase (MAPK) signaling are common in thyroid cancers.
• Some thyroid tumors respond to MAPK pathway inhibitors.
• Previous work identified L-GILZ as an anti-oncogenic protein upregulated by MAPK inhibition.

Purpose of the Study:

• To elucidate the molecular mechanism by which MAPK inhibitors exert antiproliferative effects in anaplastic thyroid cancer.
• To investigate the role of L-GILZ in mediating the effects of MAPK inhibitors.

Main Methods:

• Pharmacological inhibition of MAPK in the CAL-62 anaplastic thyroid cancer cell line.
• Assessment of L-GILZ expression and localization.
• Analysis of nuclear factor κB (NF-κB) binding and nuclear translocation.

Main Results:

• MAPK inhibition in CAL-62 cells led to increased L-GILZ expression.
• Upregulated L-GILZ directly bound to NF-κB.
• L-GILZ inhibited the nuclear translocation of NF-κB, trapping it in the cytoplasm.

Conclusions:

• A novel L-GILZ-mediated mechanism contributes to the antiproliferative effects of MAPK inhibitors in thyroid cancer.
• This mechanism involves sequestering NF-κB in the cytoplasm, thereby inhibiting proliferation.
• Understanding this pathway can inform the clinical application of MAPK inhibitors for thyroid cancer treatment.